Meeting
2015 Gastrointestinal Cancers Symposium
Phase II Pharmacodynamic Trial of Palbociclib in Patients with KRAS Mutant Colorectal Cancer.
Authors
Mark H. O'Hara
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
Mark H. O'Hara , Christine Edmonds , Michael Farwell , Rodolfo F. Perini , Daniel A. Pryma , Ursina R. Teitelbaum , Bruce J. Giantonio , Nevena Damjanov , Priti Lal , Michael D Feldman , Paul J. Zhang , David A. Mankoff , Maryann Gallagher , Angela DeMichele , David J. Vaughn , Peter J. O'Dwyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01037790
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 626)
DOI
10.1200/jco.2015.33.3_suppl.626
Abstract #
626
Poster Bd #
C18
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A randomized phase II trial of MEK and CDK4/6 inhibitors vesus tipiracil/trifluridine (TAS-102) in metastatic KRAS/NRAS mutant (mut) colorectal cancer (CRC).
First Author: Michael Sangmin Lee
Poster
2020 ASCO Virtual Scientific Program
Activity of SY-5609, an oral, noncovalent, potent, and selective CDK7 inhibitor, in preclinical models of colorectal cancer.
First Author: Liv Johannessen
Poster
2020 Gastrointestinal Cancers Symposium
Preclinical drug testing for clinical trial planning of novel combinative therapy with PI3K and MAPK inhibitors in colorectal cancer(CRC).
First Author: Cha Len Lee
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Association of candidate alterations with primary resistance to KRAS G12D targeting in colorectal cancer.
First Author: Khalid Jazieh